DEF: Teladoc Health Schedules 2026 Annual Meeting

Teladoc Health announces its 2026 Annual Meeting of Stockholders, detailing director nominations, executive compensation vote, and auditor ratification.

Summary

• Teladoc Health has scheduled its 2026 Annual Meeting of Stockholders for May 21, 2026, to be held virtually.
• The meeting will cover the election of nine director nominees, an advisory vote on executive compensation (Say-on-Pay), and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• The record date for stockholders eligible to vote is March 26, 2026.
• Key financial highlights for 2025 include $2.5 billion in total revenue and $281 million in total adjusted EBITDA.
• The company emphasizes its commitment to corporate governance best practices, including an independent Board chair, annual director evaluations, and a robust enterprise risk management program.
• Executive compensation is heavily weighted towards equity-based and incentive pay (92.9% for the CEO, 83.7% on average for other NEOs in 2025) to align with stockholder interests and company performance.
• Despite progress on strategic priorities in 2025, revenue and adjusted EBITDA performance fell short of rigorous goals, resulting in actual compensation earned being below target levels.
• The company has a related-party transaction with Cedar Gate Technologies, where director David B. Snow, Jr. is CEO, with approximately $6.3 million to be paid over three years, and $2,330,617 paid in 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily concerns routine annual meeting matters and executive compensation disclosures, with performance metrics falling short of targets but within an expected range given market conditions.

Positives

• Strong corporate governance practices are highlighted, including an independent Board chair, annual director self-evaluations, and a comprehensive enterprise risk management program.
• Executive compensation is significantly tied to long-term incentives (equity awards) to align executive interests with those of stockholders.
• The company has a clear process for identifying and evaluating director nominees, emphasizing diversity and relevant skills.
• The Audit Committee has members who are qualified as audit committee financial experts.
• The company has a clawback policy for incentive-based compensation in case of financial restatements.
• The company's international revenue grew by 12% in 2025.
• U.S. integrated care members increased by 9% in 2025.
• BetterHelp saw over 1.3 million unique users in 2025.

Negatives

• 2025 company performance fell short of rigorous revenue and adjusted EBITDA goals, leading to actual compensation earned being below target levels.
• The realized pay for named executive officers in 2025 was significantly lower than total target compensation due to company performance and stock price volatility.
• The CEO's realized pay in 2025 was less than half of the total target compensation.
• No 2024 Revenue PSUs or 2023 Net Income PSUs were earned due to performance falling short of threshold goals.
• The company experienced goodwill impairment of $71.8 million in 2025.

Risks

• The filing mentions that forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the company's control.
• Specific risk factors that could cause actual results to differ materially include changes in laws and regulations, market conditions, litigation or regulatory actions, loss of key clients or users, changes in asset valuations, difficulties in recruiting providers, impairment losses, and the success of efficiency initiatives.
• Cybersecurity risk oversight is a top priority, with the Audit Committee having primary responsibility for overseeing the company's cybersecurity program.
• The company's enterprise risk management program is designed to identify, assess, mitigate, monitor, and report on key strategic, financial, legal, technology, and operational risks.

Future Outlook

The filing does not contain specific forward-looking financial guidance but does mention ongoing strategic priorities, product innovations, market expansion, and strengthening business fundamentals as key areas of focus. The company's forward-looking statements are subject to various risks and uncertainties.

Management Comments

• "This past year was one of deliberate progress, marked by a sharpened focus on our strategic priorities and sustained execution against the backdrop of macro challenges across the healthcare industry."
• "The high utilization of equity-based and incentive compensation resulted in significantly lower total realized pay as compared to the Total Compensation showed in the 'Summary Compensation Table' below in light of 2025 Company performance falling short of our rigorous goals and extreme downward volatility in our stock price."
• "In light of our 2025 performance and downward volatility in our stock price, the Compensation Committee determined not to increase Mr. Divitas base salary for 2026 and reduced the target amount of his 2026 equity grant by 18%."
• "We believe our executive compensation program does not encourage excessive or unnecessary risk taking or create risks that are reasonably likely to have a material adverse effect on us."

Industry Context

StockSavvy.ai notes that Teladoc Health's proxy statement reflects typical trends in the telehealth and digital health sector, particularly concerning executive compensation structures that heavily rely on equity to align with volatile stock performance and long-term strategic goals. The emphasis on international growth and mental health services (BetterHelp) aligns with broader industry expansion areas.

Comparison to Industry Standards

• The company's executive compensation philosophy, heavily weighted towards equity (92.9% for CEO, 83.7% for other NEOs in 2025), aligns with industry practices aiming to link pay to performance and stockholder value, especially in growth-oriented tech and healthcare sectors.
• The peer group used for compensation benchmarking includes companies like Agilon Health, Inc., AMN Healthcare Services, Inc., Evolent Health, Inc., and Privia Health Group, Inc., indicating a focus on healthcare services and technology companies of comparable size and complexity.
• The use of Adjusted EBITDA as a key performance metric for bonuses and PSUs is a common practice in the industry for assessing operational profitability.
• The company's enterprise risk management (ERM) program and focus on cybersecurity oversight are consistent with industry standards for managing operational and data security risks in the digital health space.

Corporate Governance

Related Party Transactions

• The company has a contract with Cedar Gate Technologies for data and value-based analytics tools. David B. Snow, Jr., a director, is the CEO of Cedar Gate and owns approximately 10% of its stock. The contract involves payments of approximately $6.3 million over three years, with $2,330,617 paid in 2025.

Stakeholder Impact

• Shareholders: The election of directors, advisory vote on executive compensation, and auditor ratification directly impact shareholder governance and oversight. The compensation structure aims to align executive pay with shareholder value.
• Employees: Executive compensation is designed to attract and retain talent, with a significant portion tied to performance. The company also offers standard employee benefits.
• Management: Executive compensation is detailed, with base salaries, bonuses, and equity awards tied to performance metrics and company goals. Severance agreements are in place for named executive officers.
• Auditors: Ernst & Young LLP is proposed for reappointment as the independent registered public accounting firm, subject to stockholder ratification.

Next Steps

• Stockholders are encouraged to vote their shares for the election of directors, the advisory vote on executive compensation, and the ratification of the independent auditor.
• The company will hold its virtual Annual Meeting of Stockholders on May 21, 2026.
• The Compensation Committee will consider the outcome of the Say-on-Pay vote when making future executive compensation decisions.
• The Audit Committee will consider stockholder ratification of Ernst & Young LLP's appointment.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting. While it details director nominations and executive compensation, it also highlights that 2025 performance fell short of rigorous goals, leading to below-target compensation realization. The company's strategic priorities and risk management are outlined, but there are no significant new developments or strong positive financial indicators that would warrant a buy or strong buy recommendation at this time. The current situation suggests a 'hold' to monitor future performance against stated goals.

Keywords

Teladoc Health, Proxy Statement, Annual Meeting, Director Nominees, Executive Compensation, Say-on-Pay, Auditor Ratification, Corporate Governance, Stockholder Meeting, Virtual Meeting, Ernst & Young LLP